The clinical outcomes for infants with malignant tumors are often worse than older children due to a combination of more biologically aggressive disease in some cases, and increased toxicity—or deintensification of therapies due to concern for toxicity—in others. Especially in infants and very young children, finding the appropriate balance between maximizing treatment efficacy while minimizing toxicity—in particular late side effects—is crucial. We review here the management of malignant tumors in infants and very young children, focusing on central nervous system (CNS) malignancies and rhabdomyosarcoma.
|Journal||Pediatric Blood and Cancer|
|State||Published - May 2021|
- brain tumors
- late effects
- radiation therapy